Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04382326 · ClinicalTrials.gov registry record · Phase 3
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,997
- Enrollment target
NCT04382326: Completed Phase 3 study, sponsored by Pfizer.
NCT04382326 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,997 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (159% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04382326, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,997 participants
- Enrollment target
Study Summary
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
Primary Outcome
Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).
Interventions
- BIOLOGICAL 20-valent pneumococcal conjugate vaccine
- BIOLOGICAL 13-valent pneumococcal conjugate vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,997 participants |
| Start Date | 2020-05-20 |
| Est. Completion | 2022-09-02 |
| Phase | Phase 3 |
What the finished NCT04382326 record still lists
NCT04382326 is an interventional study that assigns participants to a tested intervention. Its 1,997 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (159% higher).
The record links to 0 conditions, and to 2 interventions - of which 20-valent pneumococcal conjugate vaccine is the first listed.
NCT04382326 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04382326 about?
NCT04382326 is a clinical study titled "20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants". 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
What is the current status of trial NCT04382326?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,997 participants. The study started on 2020-05-20. Estimated completion is 2022-09-02.
What interventions are being tested in trial NCT04382326?
The interventions under investigation include: 20-valent pneumococcal conjugate vaccine (BIOLOGICAL), 13-valent pneumococcal conjugate vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04382326?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04382326's enrollment target sits among peer trials
1,997 106th of 2000 higher than 1,895 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI